India, Oct. 19 -- Veradermics, Inc. (MANE), a late-stage biopharmaceutical company focused on therapies for pattern hair loss, announced it will review results from Part A of a Phase 3 clinical trial (Study 304) evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. The company will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET.
Pattern hair loss, also known as androgenetic alopecia, affects an estimated 80 million people in the United States 30 million women and 50 million men as per company estimates.
VDPHL01, an investigational oral, non-hormonal drug, is in phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxi...